Inadequate pain relief in ambulatory patients with human immunodeficiency virus disease in Port Harcourt

Longinus Ndubuisi Ebirim
Job Gogo Otokwala
Department of Anaesthesiology,
University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria

Objectives: To estimate the prevalence of pain in ambulatory patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) in Port Harcourt and to determine the type, site, severity, and adequacy of the treatment of pain in these patients.

Materials and methods: A cross-sectional survey was carried out at two antiretroviral therapy centers in Port Harcourt, Nigeria. A data sheet, the brief pain inventory, and the short form of the McGill pain questionnaire were used and 157 patients in various stages of HIV/AIDS participated in the study.

Results: About 83.7% (129/157) of the ambulatory patients with HIV/AIDS complained of pains. Of the patients who reported pain 61.24% (79/129) reported nociceptive pain while 38.76% (50/129) reported neuropathic pain. Chest pain was the most frequent site of pain followed by headache. About 82% (106/129) of those who complained of pain received some form of analgesic, but only 23.58% (25/106) of these obtained adequate pain relief. The majority of the participants had significant impairment of their quality of life due to the severity of their pain.

Conclusion: Pain associated with significant impairment of quality of life is common in ambulatory patients with HIV/AIDS in Port Harcourt. Whereas the majority of the patients used various pain relief methods, analgesia was inadequate.

Keywords: ambulatory HIV/AIDS patients, pain, inadequate relief

Introduction
Pain associated with disease from human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) is common and multifactorial, with different causes possible at different stages of the disease.1 Its prevalence has been estimated to be as high, if not higher than, in cancer patients.2 HIV-related pain has been found to significantly impair the quality of life of the people with this condition.3 Adequate relief of pain in these patients is therefore a necessity. However, the pain of HIV disease is often underestimated by care givers and is undertreated.4

The aim of this study was to determine the prevalence, severity, and adequacy of the treatment of HIV-related pain of ambulatory patients in Port Harcourt.

Patients and methods
After obtaining institutional research ethics committee approval, a cross-sectional survey was conducted during which data was collected at the two government-owned tertiary health care centers offering free antiretroviral therapy (ART) in Port Harcourt. These health care centers were University of Port Harcourt Teaching Hospital (UPTH)
and Braithwaite Memorial Specialist Hospital (BMSH). HIV-positive patients at both centers were being treated with a combination of zidovudine, lamivudine, and nevirapine. For those patients who were anemic, tenofovir was used to replace zidovudine in the drug combination, while for those patients who were also on antituberculosis drugs, efavirenz was used to replace nevirapine. Patients who complained of pain were offered acetaminophen or ibuprofen, but detailed assessment of the type or severity of pain was not done.

A data collection sheet, the brief pain inventory (BPI), and the short form of the McGill pain questionnaire were used to collect relevant data during the survey. The data sheet was used to record patients’ demographic data, whether on ART or not, presence of pain, and performance status of the patient. The BPI has been used previously to measure pain in HIV/AIDS patients. The BPI asks patients to report if they experienced pain because of their disease during the previous 24 hours and to rate their pain (worst, least, and on the average) on a 0–10 numerical scale.

The interview was conducted in the English language by the same investigator, but effective translation into the mother tongue was done for those participants who did not understand the English language. Informed consent was obtained from each of the participants.

All consenting, ambulant, HIV-positive patients who presented for ART at both centers within a 1 week period were included once in the study. Inpatients with HIV disease were excluded. Patients who were already diagnosed with diabetic neuropathy, arthritis, gout, sciatica, or trauma-induced pain were excluded. Analysis of collected data was done manually with the use of an electronic calculator and simple percentages.

**Results**

A total of 157 patients participated in the study. Patients’ ages ranged from 22 to 65 years, with the highest number of the patients in the 21 to 30 years age group. The sample consisted of 99 females and 58 males (Table 1).

Complaint of pain was made by 129 (83.7%) of all the patients. Among the patients who complained of pain, 92 (71.3%) were already on ART. The site of pain in these patients varied. The four most frequent sites of pain were: chest pain (38.0%), headache (25.6%), lower abdomen (16.3%), and upper abdomen (12.4%) (Table 2). About 6.9% of the patients described pain in two sites, 4.4% in three sites, and 7.0% had pain all over the body.

Using the BPI, least pain was reported by 22.0% of the patients as 0–3, by 69.2% as 4–6, and by 8.8% as 7–10 on the numerical scale. Average pain was reported by 13.1% of the patients as 0–3, by 75.9%, as 4–6 and 11.0%, as 7–10. Worst pain was reported by 4.1% as 0–3, 79.1% as 4–6, and 16.8% as 7–10 on a 0–10 numerical scale.

People who described their pain as aching, cramping, splitting, tender, or heavy according to the McGill short-form pain questionnaire were classified as having nociceptive pain while those who reported that pain was shooting, stabbing, sharp, or burning were placed in the neuropathic pain category. Based on the above categorization, 61.2% (79/129) of the patients had nociceptive pain while 38.8% (50/129) had neuropathic pain.

About 82.2% (106/129) of the patients received some analgesics (paracetamol, nonsteroidal anti-inflammatory drugs, and tegretol). Paracetamol was the analgesic drug most frequently used by the patients (Table 3). Some of the patients were using a combination of analgesic drugs and/or methods. None of the patients received any form of opioid.

**Table 1** Frequency of HIV-related pain in various age groups

| Age group (years) | Number with pain | Number without pain | Total |
|-------------------|------------------|---------------------|-------|
| 1–10              | –                | –                   | –     |
| 11–20             | –                | –                   | –     |
| 21–30             | 51               | 15                  | 66    |
| 31–40             | 33               | 5                   | 58    |
| 41–50             | 16               | 5                   | 21    |
| 51–60             | 7                | 2                   | 9     |
| 61–70             | 2                | 1                   | 3     |
| Total             | 129              | 28                  | 157   |

**Abbreviation:** HIV, human immunodeficiency virus.

**Table 2** Frequency of HIV-related pain at various body sites

| Site of pain     | Number with pains | Percentage |
|------------------|-------------------|------------|
| Chest            | 49                | 38.0       |
| Head             | 33                | 25.6       |
| Lower abdomen    | 21                | 16.3       |
| Upper abdomen    | 16                | 12.4       |
| Generalized      | 9                 | 7.0        |
| Waist            | 8                 | 6.2        |
| Lower limb       | 7                 | 5.4        |
| Perineum         | 3                 | 2.3        |
| Back             | 1                 | 0.8        |

**Abbreviation:** HIV, human immunodeficiency virus.
Among the patients who received analgesics, only 23.6% (25/106) had pain relief of 70% or more. The rest of the patients did not have adequate pain relief.

The quality of life of the majority of the patients as assessed with the BPI was adversely affected. About 86.7% (113/129) of the patients reported that pain impaired their general activity, 89.9% (116/129) reported that their mood was adversely affected while 73.4% (94/128) reported that it affected their sleep. As high as 83.0% (107/127) reported that the pain impaired their working ability, thereby reducing productivity.

**Table 3** Use of pain relief drugs/methods by patients

| Pain relief drug/method | Frequency of use | Percentage |
|------------------------|-----------------|------------|
| Paracetamol            | 77              | 59.7       |
| Ibuprofen              | 42              | 32.6       |
| Aspirin                | 26              | 20.2       |
| Tegretol               | 16              | 12.4       |
| Massage                | 16              | 12.4       |
| Herbs                  | 10              | 7.8        |
| Patent medicines       | 4               | 3.1        |

About 71.3% of the HIV patients with pain were already on ART. ART has changed the landscape of HIV/AIDS-related care in the developed world and in patients fortunate enough to have access to it. This has led to a transformed perception of HIV from being a fatal disease to a manageable chronic illness. The prevalence of pain in HIV patients is known to increase as the disease progresses and some treatments for HIV/AIDS patients may contribute to the pains suffered by them.4,13,17

The most frequent site of pain found in this study was chest pain (38.0%), followed by headache (25.6%). Headache was the most frequent site of pain in the study by Nair et al,3 followed by pain in the soles of the feet and low back. Whereas, in the multicenter study by Larue et al,4 it was digestive or mouth pain. About 20% (31/157) of the participants in this study had chest infections such as pulmonary tuberculosis, pneumonia, and bronchitis. This could have contributed to the high frequency of chest pain in our study population. The majority of the patients had pain of moderate severity, while a significant percentage (38.8%), of the participants had neuropathic pain. A frequent cause of pain at all stages of the disease is neuropathic pain associated with asymmetrical sensory polyneuropathy. These HIV-associated sensory neuropathies (HIV-SNs) are attributable to HIV itself and to some treatments.17 Some HIV treatments, in particular nucleoside reverse transcriptase inhibitors (NRTIs) such as stavudine, didanosine, and zalcitabine, are potentially neurotoxic.18,19 Although participants in this study were not being treated with any of these three drugs, the available evidence suggests that the prevalence of HIV-SN remains high among patients treated with a combination of ART drugs, even in countries where known neurotoxic antiretroviral drugs such as stavudine are no longer commonly used.20 When HIV-SN is caused by HIV itself, it is termed distal sensory polyneuropathy (DSP). It is termed antiretroviral toxic neuropathy (ATN) when it results from toxicity to antiretroviral drugs. Incidence of pain in the limbs, which would be expected to be due to DSP, was low in this study. This was in contrast to some previous studies which found incidences of 14% to 20.9%,21 even in those ambulatory HIV patients with no ART exposure. However, the incidence of DSP has been associated with ethnicity.22,23 Also, early diagnosis and early initiation of ART may decrease the risk of developing DSP.21,22 Although provision of free ART, as in this case, could enhance early diagnosis and initiation of ART, our study could not determine the interval of time between onset of illness and commencement of ART for the participants. Quality of life (general activity, mood, sleep, and ability to work) was severely impaired in the majority
of the participants in the study. Impairment of the quality of life of the patients has been known to adversely affect their productivity.3

The majority of the patients (82.0%) received some analgesic drugs, although none of them received any form of opioid. About 20.0% of the patients resorted to alternative methods of pain relief such as massage and herbal preparations, while some used “various combinations” of medicines from patent medicine stores. However, the majority of the participants did not obtain adequate pain relief from the various analgesic methods they used. Patient-related barriers to pain management have been noted,28 which were significantly associated with undertreatment of pain in HIV/AIDS patients. These include concerns about the addiction potential of some pain medications, physical discomfort associated with opioid administration (eg, injections), or side effects (eg, nausea, constipation). Patients need to be educated on the proper use of pain medications and helped to understand which therapeutic options could be beneficial to them. Whereas the anticonvulsants lamotrigine25,26 and gabapentin27,28 have been shown in placebo-controlled trials to be effective and beneficial for relief of HIV-associated painful neuropathies, carbamazepine (tegretol), which was the only anticonvulsant used by many of the participants in this study, should be avoided as it might cause adverse drug interactions with protease inhibitors and non-nucleotide reverse transcriptase inhibitors (NNRTIs) such as nevirapine and tenofovir, which some of the patients were also using.29

Palliative care and pain treatment have often been neglected in national and international responses to HIV/AIDS despite significant prevalence of pain and other symptoms in people living with HIV/AIDS.410 The assessment, evaluation, and treatment of pain should be an integral part of any comprehensive care for patients with HIV/AIDS.31 It is important for HIV clinicians to develop the knowledge and skills to deliver effective pain control and palliative care together with ART. Palliative care training for physicians caring for HIV/AIDS patients can improve the quality of pain relief provided for the patients.3

Conclusion
Pain, severe enough to significantly impair quality of life, is common in ambulatory patients with HIV/AIDS in Port Harcourt. Whereas the majority of the patients have been using various methods of pain relief, analgesia has been grossly inadequate. Mandatory training in palliative care medicine can enable the physicians caring for these patients to improve the quality of pain relief provided for them.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Borgo CD, Izzic, Chiariotti F, Del Forno A, Moscati AM, Cornacchione E, et al. Multidimensional aspect of pain in HIV infected individuals. AIDS Patient Care STDs. 2001;15:95–102.
2. Couglan M. Pain and palliative care for people living with HIV/AIDS in Asia. J Pain Palliat Care Pharmacother. 2003;17(3–4):91–104.
3. Nair SN, Mary TR, Prarthana S, Harrison P. Prevalence of pain in patients with HIV/AIDS: A cross-sectional survey in a south Indian state. Indian J Palliat Care. 2009;15(1):67–70.
4. Larue F, Fontaine R, Colleau SM. Underestimation and undertreatment of pain in HIV disease: multicentre study. BMJ. 1997;314(7073):23–28.
5. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30(2):191–197.
6. Human Resources for Health Country Profile-Nigeria. Global health work force alliance. World Health Organization; October 2008:17.
7. Tobin-West CI, Okoh DA. A three-year review of the pattern of HIV infection among pregnant women attending Braithwaite Memorial Specialist Hospital, Port Harcourt, Nigeria. Port Harcourt Med J. 2009;4:35–49.
8. Nwauche CA, Akani CI. An assessment of high risk sexual behavior and HIV transmission among migrant oil workers in the Niger Delta area of Nigeria. Niger J Clin Pract. 2006;9:48–51.
9. Udoh A, Mantell JE, Sandford T, Eigmy MA. Potential pathways to HIV/AIDS transmission in the Niger Delta of Nigeria: Poverty, migration and commercial sex. AIDS Care. 2009;21(5):567–574.
10. Bernard N, Sira R, Yabnez S, et al. Prevalence and underestimation of pain in HIV-infected patients by physicians: A cross-sectional study in a day care hospital. AIDS. 1999;13(2):293–295.
11. McCormack JP, Li R, Zaroway D, Singer J. Inadequate treatment of pain in ambulatory HIV patients. Clin J Pain. 1993;9(4):279–283.
12. Singer EJ, Zorilla C, Fahy-Chandon B, Chi S, Syndulko K, Tourtellotte WW. Painful symptoms reported by ambulatory HIV infected men in a longitudinal study. Pain. 1993;54(1):15–19.
13. UNAIDS/WHO. AIDS Epidemic Update. Geneva: UNAIDS/WHO. 2007.
14. Erhabor O, Ejele OA, Nwauche CA. The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: The Nigerian experience. Nigerian J Clin Pract. 2006;9(2):128–133.
15. Patella F Jr, Delaney K, Moorman A, et al. Declining mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–860.
16. O’Neil WM, Sherrard JS. Pain in human immunodeficiency virus disease: a review. Pain. 1993;54(1):3–14.
17. Verma A. Epidemiology and clinical features of HIV-1 associated neuropathies. J Peripher Nerv Syst. 2001;6(1):8–13.
18. Keswani SC, Pardo CA, Cherry CL, Hoke A, McArthur JC. HIV-associated sensory neuropathies. AIDS. 2002;16(16):2105–2117.
19. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf. 1998;19(6):481–494.
20. Smyth K, Affandi JS, McArthur JC, et al. Prevalence of the risk factors for HIV-associated neuropathy in Melbourne Australia 1993–2006. HIV Med. 2007;8(6):367–373.
21. Mullin S, Temu A, Kalluvya S, Grant A, Manji H. High prevalence of distal sensory polyneuropathy in antiretroviral-treated and untreated people with HIV in Tanzania. Trop Med Int Health. 2011;16(10):1291–1296.
22. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD; HIV Outpatient Study Investigations. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis. 2005;40(1):148–157.
23. Robinson-Papp J, Gonzalez-Duarte A, Simpson DM, Rivera-Mindt M, Morgello S; Manhattan HIV Brain Bank. The roles of ethnicity and antiretrovirals in HIV-associated polyneuropathy: a pilot study. *J Acquir Immune Defic Syndr*. 2009;51(5):569–573.

24. Breitbart W, Passik S, McDonald MV, et al. Patient-related barriers to pain management in ambulatory AIDS patients. *Pain*. 1998;76(1–2):9–16.

25. Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K. Placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. *Neurology*. 2000;54(11):2115–2119.

26. Simpson DM, McArthur JC, Olney R, et al; Lamotrigine HIV Neuropathy Study Team. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. *Neurology*. 2003;60(9):1508–1514.

27. Newsham G. HIV neuropathy treated with gabapentin. *AIDS*. 1998;12(2):219–221.

28. Hahn K, Arendt G, Braun JS, et al; German Neuro-AIDS Working Group. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. *J Neurol*. 2004;251(10):1260–1266.

29. Romanelli F, Jennings HR, Nath A, Ryan M, Berger J. Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals. *Neurology*. 2000;54(7):1404–1407.

30. Selwyn P, Forstein M. Overcoming the false dichotomy of curative versus palliative care for late stage of HIV/AIDS. *JAMA*. 2003;290:206–214.

31. Hirschfeld S. Pain as a complication of HIV disease. *AIDS Patient Care STDs*. 1998;12(2):91–108.